ARTICLE | Clinical News
Binimetinib: Phase III data
December 21, 2015 8:00 AM UTC
The open-label, international Phase III NEMO trial in 402 patients with unresectable or metastatic NRAS mutation-positive melanoma showed that twice-daily 45 mg binimetinib met the primary endpoint of...